View Clinical Trial (Medical Research Study)
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
| City: |
|
Cambridge |
| State: |
|
Massachusetts |
| Zip Code: |
|
|
| Conditions: |
|
Progressive Multifocal Leukoencephalopathy |
| Purpose: |
|
The purpose of this study is to explore host genetic mutations which may render individual
subjects more susceptible (or resistant) to developing Progressive Multifocal
Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid
(DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide
information about viral genotypes that may be associated with higher pathogenicity, and help
to identify individuals who may be at higher risk of developing Progressive Multifocal
Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC
Virus (JCV).
|
| Study Summary: |
|
The purpose of this study is to explore host genetic mutations which may render individual
subjects more susceptible (or resistant) to developing Progressive Multifocal
Leukoencephalopathy (PML). Deoxyribonucleic acid (DNA) will be analyzed from
natalizumab-treated subjects who develop Progressive Multifocal Leukoencephalopathy (PML).
The genetic analysis of the subjects will directly seek mutations that could identify
subjects at risk.
|
| Criteria: |
|
Inclusion Criteria:
- Approximately 50 subjects with Multiple Sclerosis (MS) or Crohn's Disease (CD) who
develop Progressive Multifocal Leukoencephalopathy (PML) while receiving natalizumab
treatment
|
| NCT ID: |
|
NCT01211639 |
| Primary Contact: |
|
Biogen-Idec Investigator
Email: neurologyclinicaltrials@biogenidec.com
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Cambridge, Massachusetts
United States
Investigator
Email: neurologyclinicaltrials@biogenidec.com
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|